Clinical trial of recombinant human endostatin injection combined with cisplatin injection in the treatment of malignant pleural effusion
10.13699/j.cnki.1001-6821.2018.07.020
- VernacularTitle:重组人血管内皮抑制素注射液联合顺铂注射液治疗恶性胸腔积液的临床研究
- Author:
Wen-Can SONG
1
;
Yu BAO
;
Jiang QIAN
;
Li-Jian ZHU
;
Si-Yuan CAO
;
Zheng-Ping TAO
Author Information
1. 池州市人民医院肿瘤科
- Keywords:
recombinant human endostatin injection;
cisplatin injection;
malignant pleural effusion;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(7):802-804
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of recombinant human endostatin injection combined with cisplatin injection in the treatment of malignant pleural effusion.Methods Sixty patients with malignant pleural effusion were randomly divided into control and treatment group with 30 cases per group.Control group was given 60 mg per time,twice a week,thoracic perfusion.Treatment group was given recombinant human endostatin 45 mg per time,twice a week,thoracic perfusion,on the basis of control group.Two groups were treated for 3 months.The dose of cisplatin is not more than 120 mg per month,and the disappearance of hydrothorax is stopped.The clinical efficacy and adverse drug reactions were compared between two groups.Results After treatment,the disease control rates of treatment and control groups were 80.00％ (24 cases / 30 cases) and 60.00％ (18 cases / 30 cases) with significant difference (P ＜ 0.05).The adverse drug reactions in two groups were gastrointestinal reactions,fever,fatigue,leukopenia,thrombocytopenia,liver and kidney function damage,and their incidences of adverse drug reactions had no statistically significant difference (all P ＞0.05).Conclusion Recombinant human endostatin injection combined with cisplatin injection has a definitive clinical efficacy in the treatment of malignant pleural effusion,without increasing the incidence of adverse drug reactions.
